


**Lloyds Pharmaceuticals (a private
unlimited company)**

Directors' Report and Unaudited Financial
Statements

Year Ended

24 August 2022

Company Number 00377277



Lloyds Pharmaceuticals (a private unlimited company)

Company Information

Directors	Richard Mark Greensmith Timothy John Martel Stephen Christopher Andrew Pickstone
Company Secretary	James Edward Hodges
Registered Number	00377277
Registered Office	103-105 Bath Road Slough Berkshire SL1 3UH

Lloyds Pharmaceuticals (a private unlimited company)

Contents

	Page
Directors' Report	1
Balance Sheet	2
Statement of Changes in Equity	3
Notes to the Financial Statements	4 - 6

Lloyds Pharmaceuticals (a private unlimited company)

Directors' Report to the members of Lloyds Pharmaceuticals (a private unlimited company) For the Year Ended 24 August 2022

The Directors present their report and the unaudited Financial Statements for the year ended 24 August 2022.

Principal activities

The Company did not trade during the current or preceding year and has not received any income or incurred any expense or recognised any other recognised gains or losses during the current or preceding year. Accordingly, no Statement of Comprehensive Income has been prepared.

In 2019 the Group commenced a project to simplify its group structure by the elimination of a number of dormant or redundant companies. As part of this project, a solvent liquidation is being considered. Accordingly, the Directors have not prepared the Financial Statements on a going concern basis. The effect of this is explained in Note 1 to the Financial Statements.

Directors

The Directors of the Company who held office during the year and up to the date of signing of the Financial Statements, unless otherwise stated, were as follows:

Richard Mark Greensmith
Timothy John Martel
Stephen Christopher Andrew Pickstone

Dividends

The Directors paid £Nil dividends during the year (2021 - Interim dividends of £4,469,000).

In preparing this report, the Directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the Board on 26 April 2023 and signed on its behalf.

DocuSigned by:
Richard Greensmith
71068916F764401...
Richard Mark Greensmith
Director

Lloyds Pharmaceuticals (a private unlimited company)
Registered number:00377277

Balance Sheet
As at 24 August 2022

		2022	2021
	Note	£000	(audited) £000
Current Assets			
Debtors due within one year	3	-	-
		<hr/>	<hr/>
Net Current Assets		-	-
		<hr/>	<hr/>
Net Assets		-	-
		<hr/> <hr/>	<hr/> <hr/>
Equity			
Share capital	4	-	-
Retained earnings		-	-
		<hr/>	<hr/>
Total Equity		-	-
		<hr/> <hr/>	<hr/> <hr/>

For the year ended 24 August 2022 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 (the "Act") relating to dormant companies.

The members have not required the Company to obtain an audit of its Financial Statements for the year in question in accordance with section 476 of the Act.

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of Financial Statements.

The Company's Financial Statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The notes on pages 4 to 6 form part of these Financial Statements.

The Financial Statements on pages 2 to 6 were approved and authorised for issue by the Board and were signed on its behalf on 26 April 2023.

DocuSigned by:

Richard Greensmith

71068916F764401...

Richard Mark Greensmith
Director

Lloyds Pharmaceuticals (a private unlimited company)

Statement of Changes in Equity For the Year Ended 24 August 2022

	Share capital £000	Total equity £000
At 25 August 2021	-	-
Comprehensive income		
Result for the financial year	-	-
Other comprehensive income for the year	-	-
Total comprehensive income for the year	-	-
Total transactions with owners	-	-
Balance at 24 August 2022	-	-

Statement of Changes in Equity For the Year Ended 24 August 2021

	Share capital £000	Retained earnings £000	Total equity £000
At 25 August 2020 (audited)	4	4,465	4,469
Comprehensive income			
Result for the financial year	-	-	-
Other comprehensive income for the year	-	-	-
Total comprehensive income for the year	-	-	-
Transactions with owners			
Capitalisation of retained earnings by way of bonus share issue	-	(4,465)	(4,465)
Capitalisation of retained earnings by way of bonus share issue	4,465	-	4,465
Capital reduction of bonus share	(4,465)	-	(4,465)
Capital reduction of bonus share impact on retained earnings	-	4,465	4,465
Capital reduction of ordinary shares	(4)	-	(4)
Capital reduction of ordinary shares impact on retained earnings	-	4	4
Dividends paid	-	(4,469)	(4,469)
Total transactions with owners	(4)	(4,465)	(4,469)
Balance at 24 August 2021 (audited)	-	-	-

The notes on pages 4 to 6 form part of these Financial Statements.

Lloyds Pharmaceuticals (a private unlimited company)

Notes to the Financial Statements For the Year Ended 24 August 2022

1. Accounting Policies

The principal accounting policies are summarised below. They have been applied consistently throughout the year and the preceding year.

1.1 General Information

Lloyds Pharmaceuticals (a private unlimited company) is a company incorporated in England and Wales. The address of the registered office is given on the Company Information page at the beginning of these statutory Financial Statements. The nature of the Company's operations and its principal activities are set out in the Directors' Report on page 1.

The Company did not trade during the year.

1.2 Statement of Compliance

The Financial Statements have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "*The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland*" ("FRS 102") and the Companies Act 2006.

1.3 Basis of Preparation

As discussed in the principal activities section of the Directors' Report, in 2019 the Group commenced a project to simplify its group structure by the elimination of a number of dormant or redundant companies. As part of this project, the Company is being considered for solvent liquidation. Accordingly, the Directors have not prepared the Financial Statements on a going concern basis. Consequently, assets have been measured and presented at their realisable values and liabilities are measured and presented at their expected settlement values.

1.4 Financial Reporting Standard 102 – Reduced Disclosure Exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these Financial Statements, as permitted by FRS 102 for qualifying entities:

- the requirements of section 3 Financial Statement Presentation paragraph 3.17(d) and section 7 Statement of Cash Flows not to prepare a Statement of Cash Flows;
- the requirements of section 33 Related Party Disclosures paragraph 33.7 not to disclose key management personnel compensation in total; and
- the requirements of section 4 Statement of Financial Position paragraph 4.12(a)(iv) not to prepare a reconciliation of the numbers of shares outstanding at the beginning and end of the year.

The Company's results are included in the publicly available consolidated Financial Statements of Reckitt Benckiser Group plc and these Financial Statements may be obtained from 103-105 Bath Road, Slough, Berkshire, SL1 3UH or at <https://www.reckitt.com>.

1.5 Dividend paid

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Lloyds Pharmaceuticals (a private unlimited company)

Notes to the Financial Statements For the Year Ended 24 August 2022

1. Accounting Policies (continued)

1.6 Financial Instruments

The Company only enters into basic financial instrument transactions that result in the recognition of basic financial assets and liabilities, including trade and other receivables and payables and loans to and from related parties. These transactions are initially recorded at transaction price, unless the arrangement constitutes a financing transaction where the transaction is measured at the present value of the future receipt discounted at a market rate of interest, and subsequently recognised at amortised cost.

(a) Financial Assets

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in comprehensive income or expense.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

(b) Financial Liabilities

Basic Financial liabilities, including loans from fellow group companies, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of future payments discounted at a market rate of interest. Debt instruments are subsequently carried at amortised cost.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled, or expires.

2. Dividend paid

	2022	2021 (audited)
	£000	£000
Interim dividend paid of £Nil (2021 - £930.84) per share	-	4,469

3. Debtors due within one year

	2022	2021 (audited)
	£000	£000
Amounts owed by Group undertakings	-	-

The amount owed by Group Undertakings due within one year is an amount of £0.41 (2021 - £0.41) which is unsecured, repayable on demand and non-interest bearing (2021 - same).

Lloyds Pharmaceuticals (a private unlimited company)

Notes to the Financial Statements For the Year Ended 24 August 2022

4. Share Capital

	2022	2021 (audited)
	£000	£000
2,000 (2021 - 2,000) Ordinary shares of €0.0001 each (2021 - €0.0001 each)	-	-
2,800 (2021 - 2,800) Ordinary shares of £0.0001 each (2021 - £0.0001 each)	-	-
1 (2021 -1) Bonus share of £0.0001 (2021 - £0.0001)	-	-
	<u> </u>	<u> </u>

The issued share capital of 2,000 ordinary shares of €0.0001 each was translated using the historic exchange rate of £1:€1.5751 on 25 August 2006.

5. Ultimate Parent Undertaking and Controlling Party

The immediate parent company is Reckitt Benckiser Limited, a company incorporated in England and Wales.

The ultimate parent company and controlling party is Reckitt Benckiser Group plc, a company incorporated in England and Wales, which is the parent undertaking of the smallest and largest group to consolidate these Financial Statements. Copies of the Group Financial Statements of Reckitt Benckiser Group plc can be obtained from 103-105 Bath Road, Slough, Berkshire, SL1 3UH or at <https://www.reckitt.com>.